Accessibility Screen-Reader Guide, Feedback, and Issue Reporting
This site is intended for healthcare professionals
Patient Site

News

<- Back

Delphinus Medical Technologies Awarded Technology Breakthrough From Premier, Inc.

August 13, 2024

Delphinus Medical Technologies Awarded Technology Breakthrough From Premier, Inc.

Delphinus Showcased its SoftVue Ultrasound Tomography System at Premier’s Breakthroughs24 Conference

Delphinus Medical Technologies, today announced that it has been awarded a national group purchasing agreement and Technology Breakthrough designation for its SoftVue™ Breast Ultrasound Tomography (UST) from Premier, inc. Delphinus is now listed as a top supplier for Premier’s members, who at their discretion, can take advantage of special pricing and terms pre-negotiated by Premier for SoftVue. SoftVue was also featured as one of the “latest and greatest” technologies at Premier’s annual conference, Breakthroughs 24.

Premier offers Technology Breakthrough designations to innovations that offer major advantages in terms of patient safety, clinical outcomes, and operational efficiencies. Over several months, Premier rigorously reviews each product submitted for consideration, where they determine if it uses innovative technology and significantly provides significant benefits for healthcare organizations and their stakeholders.

“By receiving the Technology Breakthrough agreement from Premier, SoftVue is recognized as a product that represents a major advancement in driving high-quality, cost-effective care, and we couldn’t agree more,” said Scott White, CEO of Delphinus Medical Technologies. “We look forward to continuing to expand our network of customers, through Premier’s alliance, that use our breast imaging technology as an effective supplemental screening method, in combination with mammogram, for women with dense breasts.”

SoftVue is approved by the FDA for same-day screening as mammography, and when paired with mammography, shows superiority in cancer detection for women with dense breasts compared to mammography alone. SoftVue has been shown to identify up to 25 percent more cancers while also decreasing unnecessary call-backs and short term follow-up in women with dense breasts. Delphinus designed the system to address the fact that breast cancer screening with mammography alone reduces mortality by only 13% in women with dense breasts. SoftVue can be performed during the same visit as the women’s mammogram, saving patients time and improving the diagnostic clinical workflow for breast centers.

Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,350 U.S. hospitals and 300,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, consulting and other services, Premier enables better care and outcomes at a lower cost.

We use cookies to enhance user experience, analyze performance and traffic on our website, and personalize content. We also share information about your use of our website with our advertising and analytics partners. For more information on our use of cookies and information about your use of our site, please see our Privacy Policy.